The North Dublin Population Stroke Study (NDPSS) is a prospective population-based cohort study of stroke and transient ischemic attack. Methodology and definitions are previously described 4 (online-only Data Supplement). We recruited individuals with stroke occurring over a 1-year period in 2006. Qualifying event (QE) was coded as first-ever stroke (QE-FES) or prior stroke (QE-PS) if remote stroke existed before the study onset.
R ecent literature reports declining incidence and case fatality after stroke, coincident with improved vascular risk factor control. [1] [2] [3] [4] It is also possible that wider use of antiplatelet, antihypertensive, and statin medications may influence late stroke fatality and functional outcome via reduced recurrent vascular events. [4] [5] [6] However, few recent population-based data exist on rates and determinants of late stroke recurrence. 6 We aimed to quantify rates and predictors of stroke recurrence 2 years after stroke in the era of modern vascular preventive therapy.
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range, 2-11). Data were available on prescribed medications in 92.9% of survivors beyond day 28 (Table II in the onlineonly Data Supplement).
Recurrent Stroke Rates and Subtypes
At 2 years, follow-up data were complete for stroke recurrence status in 91.4% (518/567). Recurrent stroke occurred in 46 patients. On life-table analysis, the cumulative rate of recurrent stroke was 3.8% at 28 days and 10.8% at 2 years. Twoyear recurrence was 11.5% for ischemic stroke and 5.7% for ICH (Table 2 ). Late recurrence rates were higher for patients, who qualified with QE-PS compared with QE-FES (P=0.004; Table 3 ; Figure I in the online-only Data Supplement).
Of the 46 recurrent strokes, brain imaging was performed in 93.5% (43/46). Recurrent stroke subtypes were ischemic in 84.8% (39/46), ICH in 8.7% (4/46) , and unknown in 6.5% (3/46) . Recurrent stroke subtype was strongly associated with initial subtype (P<0.001).
On Cox regression in 28-day survivors, QE-PS (hazard ratio, 3.3; P=0.005) and hyperlipidemia (hazard ratio, 2.9; P=0.01) remained as independent predictors of 2-year recurrence (Table III and Figure II in the online-only Data  Supplement) .
Median deterioration in Rankin score was greater at 2 years in patients with stroke recurrence (P=0.03). Two-year case fatality was 38.6%. Stroke recurrence was not associated with higher 2-year fatality (online-only Data Supplement).
Discussion
We report rates and predictors of early and late recurrent stroke in a recent population-based study with gold-standard rigorous ascertainment methods, high rates of modern stroke preventive medication utilization, and high follow-up rates. Despite rigorous follow-up for recurrent events and inclusion of very early recurrences, the rate of stroke recurrence at 2 years in our study was 10.8%. Direct comparison of studies, which report stroke recurrence, is difficult because of variation in factors, such as study setting, methodology, case mix, and study era.
7 Allowing for these caveats, the recurrence rates observed in FES patients in our study (7.4% at 1 and 8.7% at 2 years) are at the lower limits of the ranges reported at these time intervals from developed countries in the past decade. 5 We suspect that our relatively low recurrence rate may relate to the high rates of preventive medication use in our cohort. One systematic review found a temporal reduction of 5-year stroke recurrence rates in recent epidemiological studies, 5 whereas another review found that recurrent stroke rates had decreased substantially since 1960, associated with increased antiplatelet medication use and blood pressure control. 8 Our findings are also consistent with data from the Vitamin Intervention for Stroke Trial (VISP) trial, which reported 2-year recurrent stroke rates of 7.3% in patients appropriately prescribed secondary prevention medications compared with 15.9% in those who were not. 3 Although we were unable to detect an association between preventive medication use and recurrence, this cannot be fully excluded, given that our data set may have lacked statistical power to detect a modest association.
We found that PS and hyperlipidemia were independent predictors of late recurrent stroke. Although we observed high rates of statin prescribing, our study predated the Stroke Prevention by Aggressive Reduction of Cholesterol Levels (SPARCL) trial and subsequent updated lipid-lowering guidelines. 3 Our findings emphasize the high future risk of patients with 2 or more cerebrovascular events, which persists despite modern preventive therapies. The relationship of lipids with recurrent stroke in earlier studies is inconsistent, possibly reflecting subtype-specific risk or heterogeneity of methods. A recent large study reported that baseline dyslipidemia was independently associated with increased risk of late stroke recurrence. 9 The strengths of our study include its prospective population-based design with rigorous ascertainment, high rates of late follow-up, in-person physician verification and subtyping of recurrences, and inclusion of ICH. We performed detailed analyses, including modern medication data, and included first-ever and PS cases.
Our main limitation is that our sample size may have been insufficient for detection of modest associations between candidate predictor variables and recurrent stroke.
For investigators considering new randomized trials, our data provide further evidence that low recurrence rates are to be anticipated, leading to a requirement for very large sample sizes to demonstrate efficacy of new candidate agents for secondary prevention after stroke. 
Sources of Funding

Case Ascertainment
The source population was defined as 294,592 individuals by the Irish census-based District Electoral Division system. Ethical approval was obtained from all participating institutions. Informed consent was obtained from all patients, or next-of-kin. Supplementary sources included daily review of relevant in-patient consultation referrals, medical notes of all patients assessed but not admitted at emergency departments, and computerised requests for brain and vascular imaging. Coroner and mortuary records were reviewed to identify fatal cases. Community ascertainment involved at least monthly screening for new stroke cases presenting to 180/190 (94%) of North Dublin general practitioners and/or occurring in 17/18 (95%) of area nursing homes. A daily minor Stroke/TIA clinic was also established to promote referral and ascertainment of community-treated patients.
Patients were recruited within 72 hours of the qualifying event. All suspected cases were reviewed by a study physician and assessed in-person for diagnostic queries and recurrences. Case eligibility was agreed at weekly meetings. Acute neurological severity (<72 hours) was assessed prospectively using the National Institutes of Health Stroke Scale (NIHSS). Functional outcome was assessed by modified Rankin score (mRS).
Stroke recurrence, fatality, and disability were assessed at 72 hours, 7-day, 28-day, 90-day, one and two year time-intervals, by interview with patient, family or healthcare staff conducted by a trained researcher. All recurrent strokes were verified by in-person physician assessment and/or review of medical files and imaging.
Definitions
The WHO definition of stroke was used to identify cases 1 . Ischaemic stroke (IS) was defined in the presence of an appropriate clinical syndrome, with evidence of cerebral infarction on brain magnetic resonance imaging (MRI) or computerised tomography (CT), or normal neuro-imaging with absence of brain haemorrhage, or pathological evidence of recent cerebral infarction at autopsy. Primary intracerebral haemorrhage (PICH) was defined in the presence of an appropriate clinical syndrome, and evidence of acute intra-parenchymal haematoma on brain imaging or autopsy. Subarachnoid haemorrhage (SAH) was defined as an appropriate clinical syndrome, with supportive brain imaging, cerebrospinal fluid or autopsy findings. If neither brain imaging nor pathological examination were performed, the pathological subtype was coded as 'unknown'. A single trained research physician applied the Trial of Org 10172 in Acute Stroke Treatment (TOAST) classification system for ischaemic stroke subtyping 2 . Subtype-specific risk factors are previously described 3 .
Stroke recurrence during the study follow-up period was defined as a discrete new neurological deficit consistent with WHO definition occurring >24 hours after the qualifying (entry) event after excluding early deterioration caused by the initial stroke, stroke progression or other syndrome 4 .
The change in mRS (delta-mRS) between 7 days and 2 years was derived as (2-year mRS minus 7-day mRS). As higher mRS values indicate worse functional ability, negative values for delta-mRS indicate recovery. Excellent outcome was defined as mRS 0-1 (no disability). Good outcome was defined as mRS 0-2 (independent).
Eligibility criteria
Inclusion criteria for this analysis were: (1) new stroke event (ischaemic, intracerebral haemorrhage [ICH], subarachnoid haemorrhage [SAH]) during the ascertainment year, including patients with QE-FES and a qualifying-event of new stroke event in the context of prior stroke (QE-PS) (2) age >18 years (3) consent available for patient follow-up. Patients with TIA as their study qualifying event were excluded.
Statistical Analyses
A survival-based approach using life-table analysis and Kaplan-Meier curves was used for time-to-event analysis at defined time intervals following stroke onset, with categorical comparisons performed by the log-rank test and log-rank test for trend. A log-log plot of survival and Kaplan-Meier curves were examined to evaluate for violation of the proportional hazards assumption. Forward step-wise multivariable Cox regression was used to identify variables associated with the likelihood of stroke recurrence and fatality.
Supplemental Results
Patient Characteristics
Pathological subtype was confirmed in 544 (95.9%) patients (533 on brain imaging and 11 at autopsy). Mean age was 70.9 years and 9.2% were treated in the community. Clinical characteristics analysed by stroke subtype are detailed in Supplemental Table I . Data was available on prescribed medications in 94.5% (536/567) pre-stroke and 92.9% of survivors beyond day 28 (417/450). No difference in medication use was apparent among patients with and without stroke recurrence (Supplemental Table II ).
Factors associated with recurrent stroke
On bivariate Cox regression, stroke recurrence at 2 years was associated with QE-PS (HR 2.48, p=0.006) and hyperlipidaemia (HR 2.20, p=0.008), but not age, gender, other vascular risk factors, TOAST category, or secondary prevention medication use. When stratified by time-interval from qualifying stroke onset, no variables were associated with early (<day 28) recurrence while QE-PS (HR 4.62, p<0.001) and hyperlipidaemia (HR 3.77, p=0.001) remained associated with late (29 days-2 years) recurrence (Supplemental Figure I and II). On stepwise Cox regression modelling (including age, gender, QE-PS and hyperlipidaemia), QE-PS (HR 1.95, p=0.06) and hyperlipidaemia (HR 1.97, p=0.03) remained as independent predictors of 2-year recurrence. These associations were stronger when the analysis was restricted to surviving patients at 28 days (QE-PS HR 3.32, p=0.005, hyperlipidaemia HR 2.92, p=0.01) (Supplemental Table III ). Our results were unchanged when the analysis was repeated in patients with ischaemic stroke.
Recurrent stroke pathological subtype:
Of the 46 recurrent strokes, brain imaging was performed in 93.5% (43/46 patients; 54.3% (25/46) CT, 21.7% (10/46) MRI, 17.4% (8/46) both). Among patients qualifying with ischaemic stroke, 88.4% of recurrences were ischaemic. Two recurrences occurred in patients who qualified with ICH, both recurrent ICH. Of these, one was biopsy-confirmed amyloid angiopathy with vasculitis and the other a basal ganglia ICH in a hypertensive patient treated with aspirin at the time of ICH recurrence.
Rates and Determinants of 2 Year Fatality
At two years, follow-up survival data was available in 96.1% (545/567). On life-table analysis, the overall 28-day (early) case-fatality rate was 20.7% (117/567). In survivors beyond day 28, a further 22.6% (97/450) died, resulting in an overall 2-year case-fatality rate of 38.6% (Supplemental Table IV ).
In all stroke patients, univariate Cox regression analysis showed that fatality at 2 years was associated with greater age (HR per 1-year increase 1.05, p<0.001), higher NIHSS (HR per 1-point rise 1.12, p<0.001), and atrial fibrillation (HR 1.74, p<0.001). Lower fatality was found with smoking (HR 0.53, p<0.001), statin (HR 0.24, p<0.001) and anti-platelet treatment after the qualifying event (HR 0.56, p<0.001). Our findings were unchanged when the analysis was repeated in the subgroup of patients with first-ever ischaemic stroke. However, associations were also observed between 2-year fatality and TOAST cardioembolic (HR 8.55, p<0.001) and large artery categories (HR 3.19, p=0.06, reference TOAST small-vessel category).
On multivariate Cox regression analysis, age (HR per 10-year increase 1.52, p<0.001), NIHSS (HR per 1-point rise 1.12, p<0.001), pre-stroke mRS (HR per 1-point rise 1.21, p=0.001) and atrial fibrillation (HR 1.79, p=0.001) were independently predictive of fatality at 2 years whilst post stroke statins (HR 0.37, p<0.001) predicted lower fatality. Independent predictors of early (<28 days) fatality were NIHSS (HR 1.14, p<0.001), hypertension (HR 1.66, p=0.05), and pre-stroke mRS (HR per 1-point rise 1.15, p=0.05) . When post-stroke antiplatelet, antihypertensive, and statins were added to the model, statins (HR 0.22, p<0.001) were independent predictors of lower risk of early death. When NIHSS was removed from the model, both ICH (HR 2.75, p<0.001) and SAH (HR 3.87, p<0.001) became independently predictive of 28-day fatality (Supplemental Table V) .
In survivors at 28 days, age (HR per 10-year increase 1.99, p=0.001), NIHSS (HR 1.12, p<0001), pre-stroke mRS (HR 1.25, p=0.007) and atrial fibrillation (HR 2.40, p=0.001) predicted late death by 2 years. After addition of medications to the model, again statins (HR 0.45, p=0.001) but not antiplatelet or antihypertensive medications independently predicted lower risk of late fatality (Supplemental Table V ).
Compared with QE-FES, patients with QE-PS had similar early (log-rank p=0.8) but higher late case-fatality (log-rank p=0.02). Compared with ischaemic stroke, ICH and SAH had higher fatality within 28 days (p<0.001). On multivariate Cox regression analysis, age category (HR per 10-year increase 1.52, p<0.001), NIHSS (HR per 1-point rise 1.12, p<0.001), pre-stroke mRS (HR per 1-point rise 1.21, p=0.001) and atrial fibrillation (HR 1.79, p=0.001) were independently predictive of fatality at 2 years whilst post stroke statins (HR 0.37, p<0.001) predicted lower fatality. No association was observed between stroke recurrence and fatality at early time-intervals or 2 years.
Recurrent stroke and functional outcome:
In the entire cohort, the median change in mRS (delta-mRS) between 7 days and 2 years was 0 (IQR -1, +1). In patients with recurrent stroke, the median 2-year mRS change was +1 (indicating death or functional decline) compared with a median of 0 in those without recurrence (p=0.03). When repeated in patients who qualified with ischaemic stroke, these results were unchanged (p=0.02).
Recurrent stroke was associated with a trend towards lower likelihood of excellent outcome (mRS 0-1) at 2 years (5.3% versus 9.6%, p=0.08) (Supplemental Table VI) . However, no difference in proportions of patients with good outcome (mRS 0-2) was observed in patients stratified by recurrent stroke status (p=0.4). All stroke (FES+PS) model included age category # (<65 years, 65-74 years, 75-84 years and >85 years), sex, NIHSS, atrial fibrillation, pre-stroke mRS, qualifying event prior stroke (QE-PS), stroke subtype (dummy variable, compared with ischaemic stroke), and post-stroke statin. Hypertension was included in the model for early (day28) fatality, as it was associated with early fatality on bivariate analysis. Recurrent stroke was not associated with fatality at any time interval. 
Supplemental Tables
NS, not significant
Supplemental Figure Legends and Figures
Supplemental Figure I . Kaplan-Meier curve showing stroke recurrence-free survival for those with qualifying event first-ever stroke (QE-FES) (solid line) and those with qualifying event of new stroke with remote prior stroke before the study ascertainment period (QE-PS) (----).
Supplemental Figure II . Kaplan-Meier curve showing stroke recurrence-free survival for those without hyperlipidaemia (solid line) and those with hyperlipidaemia (----).
